25 XP   0   0   10

Beam Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Beam Therapeutics Inc together

PenkeI guess you are interested in Beam Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Beam Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Beam Therapeutics Inc

I send you an email if I find something interesting about Beam Therapeutics Inc.

Quick analysis of Beam Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Beam Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
9.5%

What is your share worth?

Current worth
$11.87
Expected worth in 1 year
$14.75
How sure are you?
57.1%

+ What do you gain per year?

Total Gains per Share
$2.88
Return On Investment
8.5%

For what price can you sell your share?

Current Price per Share
$33.96
Expected price per share
$30.29 - $51.60
How sure are you?
50%

1. Valuation of Beam Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$33.96

Intrinsic Value Per Share

$82.58 - $100.08

Total Value Per Share

$94.44 - $111.95

2. Growth of Beam Therapeutics Inc (5 min.)




Is Beam Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$981.3m$769.2m$64m7.7%

How much money is Beam Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$30m-$62.9m$32.8m109.5%
Net Profit Margin-318.1%-457.7%--

How much money comes from the company's main activities?

3. Financial Health of Beam Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#61 / 1031

Most Revenue
#81 / 1031

Most Profit
#829 / 1031

Most Efficient
#710 / 1031

What can you expect buying and holding a share of Beam Therapeutics Inc? (5 min.)

Welcome investor! Beam Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Beam Therapeutics Inc.

What can you expect buying and holding a share of Beam Therapeutics Inc?

First you should know what it really means to hold a share of Beam Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Beam Therapeutics Inc is $33.96. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Beam Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Beam Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $11.87. Based on the TTM, the Book Value Change Per Share is $0.72 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Beam Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps1.735.1%-0.41-1.2%-0.80-2.3%-0.64-1.9%-0.62-1.8%
Usd Book Value Change Per Share2.336.9%0.722.1%-0.29-0.8%0.511.5%0.571.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.0%0.010.0%
Usd Total Gains Per Share2.336.9%0.722.1%-0.29-0.8%0.521.5%0.571.7%
Usd Price Per Share27.22-28.46-45.69-41.21-39.25-
Price to Earnings Ratio3.94--3.88--30.34--16.43--15.65-
Price-to-Total Gains Ratio11.70-23.21-505.38-127.07-127.07-
Price to Book Ratio2.29-2.83-4.85-6.71-6.39-
Price-to-Total Gains Ratio11.70-23.21-505.38-127.07-127.07-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share33.96
Number of shares29
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.720.51
Usd Total Gains Per Share0.720.52
Gains per Quarter (29 shares)20.9115.07
Gains per Year (29 shares)83.6260.30
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10847415950
201671582119110
302512423178170
403343264237230
504184105297290
605024946356350
705855787415410
806696628474470
907537469534530
10083683010593590

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.020.00.04.8%1.020.00.04.8%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%11.08.01.055.0%12.08.01.057.1%12.08.01.057.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%2.00.018.010.0%2.00.019.09.5%2.00.019.09.5%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%11.08.01.055.0%12.08.01.057.1%12.08.01.057.1%

Fundamentals of Beam Therapeutics Inc

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-03-20 11:17:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Beam Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Beam Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Beam Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 45.2% means that $0.45 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Beam Therapeutics Inc:

  • The MRQ is 45.2%. The company is making a huge profit. +2
  • The TTM is -318.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ45.2%TTM-318.1%+363.2%
TTM-318.1%YOY-457.7%+139.6%
TTM-318.1%5Y-447,946.6%+447,628.5%
5Y-447,946.6%10Y-426,615.8%-21,330.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ45.2%-171.8%+217.0%
TTM-318.1%-205.8%-112.3%
YOY-457.7%-262.1%-195.6%
5Y-447,946.6%-455.6%-447,491.0%
10Y-426,615.8%-589.0%-426,026.8%
1.1.2. Return on Assets

Shows how efficient Beam Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Beam Therapeutics Inc to the Biotechnology industry mean.
  • 9.8% Return on Assets means that Beam Therapeutics Inc generated $0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Beam Therapeutics Inc:

  • The MRQ is 9.8%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -2.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ9.8%TTM-2.5%+12.3%
TTM-2.5%YOY-4.5%+2.0%
TTM-2.5%5Y-8.7%+6.2%
5Y-8.7%10Y-9.0%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.8%-12.5%+22.3%
TTM-2.5%-12.2%+9.7%
YOY-4.5%-11.2%+6.7%
5Y-8.7%-13.4%+4.7%
10Y-9.0%-14.7%+5.7%
1.1.3. Return on Equity

Shows how efficient Beam Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Beam Therapeutics Inc to the Biotechnology industry mean.
  • 14.6% Return on Equity means Beam Therapeutics Inc generated $0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Beam Therapeutics Inc:

  • The MRQ is 14.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -4.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ14.6%TTM-4.8%+19.3%
TTM-4.8%YOY-8.3%+3.6%
TTM-4.8%5Y-13.6%+8.9%
5Y-13.6%10Y-13.9%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.6%-15.8%+30.4%
TTM-4.8%-15.7%+10.9%
YOY-8.3%-13.9%+5.6%
5Y-13.6%-18.3%+4.7%
10Y-13.9%-19.2%+5.3%

1.2. Operating Efficiency of Beam Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Beam Therapeutics Inc is operating .

  • Measures how much profit Beam Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Beam Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 42.0% means the company generated $0.42  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Beam Therapeutics Inc:

  • The MRQ is 42.0%. The company is operating very efficient. +2
  • The TTM is -398.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ42.0%TTM-398.0%+440.0%
TTM-398.0%YOY-604.6%+206.5%
TTM-398.0%5Y-309,105.0%+308,707.0%
5Y-309,105.0%10Y-294,385.8%-14,719.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ42.0%-299.1%+341.1%
TTM-398.0%-210.1%-187.9%
YOY-604.6%-279.7%-324.9%
5Y-309,105.0%-459.9%-308,645.1%
10Y-294,385.8%-596.9%-293,788.9%
1.2.2. Operating Ratio

Measures how efficient Beam Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.58 means that the operating costs are $0.58 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Beam Therapeutics Inc:

  • The MRQ is 0.580. The company is very efficient in keeping operating costs low. +2
  • The TTM is 5.032. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.580TTM5.032-4.452
TTM5.032YOY7.212-2.180
TTM5.0325Y3,792.232-3,787.200
5Y3,792.23210Y3,611.650+180.582
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5802.861-2.281
TTM5.0323.193+1.839
YOY7.2123.615+3.597
5Y3,792.2325.560+3,786.672
10Y3,611.6507.396+3,604.254

1.3. Liquidity of Beam Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Beam Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.89 means the company has $5.89 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Beam Therapeutics Inc:

  • The MRQ is 5.891. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.190. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.891TTM5.190+0.702
TTM5.190YOY5.172+0.017
TTM5.1905Y5.236-0.047
5Y5.23610Y5.263-0.027
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.8913.986+1.905
TTM5.1904.440+0.750
YOY5.1725.552-0.380
5Y5.2366.158-0.922
10Y5.2636.492-1.229
1.3.2. Quick Ratio

Measures if Beam Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Beam Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 9.46 means the company can pay off $9.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Beam Therapeutics Inc:

  • The MRQ is 9.456. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.892. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.456TTM8.892+0.564
TTM8.892YOY9.167-0.274
TTM8.8925Y8.425+0.467
5Y8.42510Y8.296+0.129
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.4563.638+5.818
TTM8.8924.168+4.724
YOY9.1675.515+3.652
5Y8.4256.012+2.413
10Y8.2966.209+2.087

1.4. Solvency of Beam Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Beam Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Beam Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33 means that Beam Therapeutics Inc assets are financed with 32.8% credit (debt) and the remaining percentage (100% - 32.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Beam Therapeutics Inc:

  • The MRQ is 0.328. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.388. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.328TTM0.388-0.061
TTM0.388YOY0.447-0.059
TTM0.3885Y0.350+0.039
5Y0.35010Y0.342+0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3280.335-0.007
TTM0.3880.330+0.058
YOY0.4470.267+0.180
5Y0.3500.367-0.017
10Y0.3420.378-0.036
1.4.2. Debt to Equity Ratio

Measures if Beam Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Beam Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 48.7% means that company has $0.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Beam Therapeutics Inc:

  • The MRQ is 0.487. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.640. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.487TTM0.640-0.153
TTM0.640YOY0.811-0.171
TTM0.6405Y0.569+0.072
5Y0.56910Y0.553+0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4870.376+0.111
TTM0.6400.398+0.242
YOY0.8110.334+0.477
5Y0.5690.429+0.140
10Y0.5530.476+0.077

2. Market Valuation of Beam Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Beam Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Beam Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of 3.94 means the investor is paying $3.94 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Beam Therapeutics Inc:

  • The EOD is 4.917. Based on the earnings, the company is cheap. +2
  • The MRQ is 3.941. Based on the earnings, the company is cheap. +2
  • The TTM is -3.881. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD4.917MRQ3.941+0.976
MRQ3.941TTM-3.881+7.822
TTM-3.881YOY-30.336+26.456
TTM-3.8815Y-16.428+12.547
5Y-16.42810Y-15.646-0.782
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.917-2.643+7.560
MRQ3.941-2.418+6.359
TTM-3.881-2.742-1.139
YOY-30.336-4.123-26.213
5Y-16.428-6.257-10.171
10Y-15.646-6.478-9.168
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Beam Therapeutics Inc:

  • The EOD is 5.340. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 4.280. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -3.151. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.340MRQ4.280+1.060
MRQ4.280TTM-3.151+7.431
TTM-3.151YOY-6.683+3.532
TTM-3.1515Y-50.726+47.576
5Y-50.72610Y-48.311-2.416
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.340-3.244+8.584
MRQ4.280-2.939+7.219
TTM-3.151-3.478+0.327
YOY-6.683-5.592-1.091
5Y-50.726-8.473-42.253
10Y-48.311-8.881-39.430
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Beam Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.29 means the investor is paying $2.29 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Beam Therapeutics Inc:

  • The EOD is 2.862. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.294. Based on the equity, the company is underpriced. +1
  • The TTM is 2.828. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.862MRQ2.294+0.568
MRQ2.294TTM2.828-0.534
TTM2.828YOY4.848-2.020
TTM2.8285Y6.713-3.885
5Y6.71310Y6.393+0.320
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8622.124+0.738
MRQ2.2942.041+0.253
TTM2.8282.118+0.710
YOY4.8482.915+1.933
5Y6.7133.682+3.031
10Y6.3934.114+2.279
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Beam Therapeutics Inc.

3.1. Institutions holding Beam Therapeutics Inc

Institutions are holding 89.611% of the shares of Beam Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31ARK Investment Management LLC11.5041.513893938896099986.9445
2023-12-31Vanguard Group Inc8.77430.004371648763499065.1344
2023-12-31BlackRock Inc8.15850.004666620431393882.137
2023-12-31FMR Inc7.56860.01296180322-317509-4.8864
2023-12-31State Street Corporation5.65330.0061461635847422911.4489
2023-12-31Morgan Stanley - Brokerage Accounts5.12420.0141843423662213701.4
2023-12-31Farallon Capital Management, L.L.C.5.0280.55484105753-376086-8.3913
2023-12-31Temasek Holdings Ltd.3.76710.46873076117-1241672-28.7571
2023-12-31Nikko Asset Management Americas Inc2.88780.6161235809171591143.5952
2023-12-31Sumitomo Mitsui Trust Holdings Inc2.88780.0475235809171591143.5952
2023-12-31MWG Management Ltd.2.874153.739234693400
2023-12-31Geode Capital Management, LLC1.92910.004515752791065317.2532
2023-09-30Redmile Group, LLC1.79991.68181469725-15474-1.0419
2023-09-30Citadel Advisors Llc1.44130.00611176915857371268.3108
2023-12-31Goldman Sachs Group Inc1.18580.0024968300506583109.7172
2023-12-31Yiheng Capital LLC1.03541.326784550028500050.8475
2023-09-30SC China Holding Ltd0.97492.053179608900
2023-12-31Baillie Gifford & Co Limited.0.93580.0165764123-111624-12.7461
2023-12-31Bellevue Group AG0.85090.289369482100
2023-12-31Northern Trust Corp0.81870.0033668542139342.1286
Total 75.199562.361561406110+6374610+10.4%

3.2. Funds holding Beam Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31ARK Disruptive Innovation Full Composite7.87781.886264328113509385.7702
2024-02-29ARK Innovation ETF7.16662.81485852105-14608-0.249
2024-02-29SPDR® S&P Biotech ETF3.91011.59233192938596401.9034
2023-12-31ARK Genomic Revolution3.15323.156257487032734614.5647
2024-02-29Vanguard Total Stock Mkt Idx Inv2.81520.00592298835-9079-0.3934
2024-02-29ARK Genomic Revolution ETF2.76634.77052258927114180.508
2024-02-29Vanguard Small Cap Index2.31560.05311890866176620.9429
2024-02-29iShares Russell 2000 ETF2.1520.11131757239-287-0.0163
2024-01-31Nikko AM ARK Disruptive Innovation A USD1.47231.0461202271-6224-0.515
2024-01-31Fidelity Growth Compy Commingled Pl O1.34860.03751101232194041.7936
2024-02-29Vanguard Small Cap Growth Index Inv1.29950.12011061179176231.6887
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.28950.04081052988-11008-1.0346
2024-01-31Fidelity Select Biotechnology1.25330.5413102345000
2024-01-31Fidelity Growth Company Fund0.97330.0354794811-7549-0.9408
2024-01-31Nikko AM ARK Pstv Chg Innovt P JPY Acc0.96550.843978844400
2023-12-31Fidelity Small Cap Index0.88470.0774722394365815.334
2023-09-30BB Biotech AG Ord0.84880.683969312100
2024-02-29iShares Russell 2000 Growth ETF0.70550.200457605619200.3344
2024-02-29iShares Biotechnology ETF0.64270.2725524818-2360-0.4477
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.53240.0411434738121002.863
Total 44.372918.330436234093+803517+2.2%

3.3. Insider Transactions

Insiders are holding 1.742% of the shares of Beam Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-13Fmr LlcSELL156530.76
2024-01-31John M EvansSELL6000025.33
2024-01-03Christine BellonSELL190726.42
2023-10-30Amy SimonSELL344818.7
2023-10-02Christine BellonSELL38822.85
2023-07-24Giuseppe CiaramellaSELL120632.01
2023-07-21Giuseppe CiaramellaSELL15532432.06
2023-07-10Amy SimonSELL39130.48
2023-04-03Giuseppe CiaramellaSELL191830.31
2023-04-03John M EvansSELL516130.31
2023-04-03Terry-ann BurrellSELL245430.31

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Beam Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.3270.721+223%-0.286+112%0.511+355%0.565+312%
Book Value Per Share--11.86610.168+17%9.421+26%6.425+85%6.197+91%
Current Ratio--5.8915.190+14%5.172+14%5.236+13%5.263+12%
Debt To Asset Ratio--0.3280.388-16%0.447-27%0.350-6%0.342-4%
Debt To Equity Ratio--0.4870.640-24%0.811-40%0.569-14%0.553-12%
Dividend Per Share----0%-0%0.009-100%0.008-100%
Eps--1.727-0.411+124%-0.797+146%-0.636+137%-0.620+136%
Free Cash Flow Per Share--1.590-0.565+136%-0.081+105%-0.319+120%-0.312+120%
Free Cash Flow To Equity Per Share--1.9970.280+614%0.261+666%0.604+231%0.637+214%
Gross Profit Margin--0.9620.991-3%1.000-4%0.998-4%0.998-4%
Intrinsic Value_10Y_max--100.083--------
Intrinsic Value_10Y_min--82.579--------
Intrinsic Value_1Y_max--0.321--------
Intrinsic Value_1Y_min--0.309--------
Intrinsic Value_3Y_max--8.362--------
Intrinsic Value_3Y_min--7.834--------
Intrinsic Value_5Y_max--25.324--------
Intrinsic Value_5Y_min--22.869--------
Market Cap2773095356.160+19%2251156660.4402330678283.510-3%3730940130.240-40%3366902820.558-33%3206574114.817-30%
Net Profit Margin--0.452-3.181+804%-4.577+1113%-4479.466+991977%-4266.158+944745%
Operating Margin--0.420-3.980+1047%-6.046+1539%-3091.050+735747%-2943.858+700716%
Operating Ratio--0.5805.032-88%7.212-92%3792.232-100%3611.650-100%
Pb Ratio2.862+20%2.2942.828-19%4.848-53%6.713-66%6.393-64%
Pe Ratio4.917+20%3.941-3.881+198%-30.336+870%-16.428+517%-15.646+497%
Price Per Share33.960+20%27.22028.455-4%45.690-40%41.215-34%39.252-31%
Price To Free Cash Flow Ratio5.340+20%4.280-3.151+174%-6.683+256%-50.726+1285%-48.311+1229%
Price To Total Gains Ratio14.596+20%11.69923.212-50%505.377-98%127.066-91%127.066-91%
Quick Ratio--9.4568.892+6%9.167+3%8.425+12%8.296+14%
Return On Assets--0.098-0.025+126%-0.045+146%-0.087+189%-0.090+192%
Return On Equity--0.146-0.048+133%-0.083+157%-0.136+194%-0.139+195%
Total Gains Per Share--2.3270.721+223%-0.286+112%0.520+348%0.573+306%
Usd Book Value--981329000.000833354750.000+18%769295000.000+28%525266200.000+87%506635809.524+94%
Usd Book Value Change Per Share--2.3270.721+223%-0.286+112%0.511+355%0.565+312%
Usd Book Value Per Share--11.86610.168+17%9.421+26%6.425+85%6.197+91%
Usd Dividend Per Share----0%-0%0.009-100%0.008-100%
Usd Eps--1.727-0.411+124%-0.797+146%-0.636+137%-0.620+136%
Usd Free Cash Flow--131484000.000-45731750.000+135%-6606000.000+105%-25952450.000+120%-25392238.095+119%
Usd Free Cash Flow Per Share--1.590-0.565+136%-0.081+105%-0.319+120%-0.312+120%
Usd Free Cash Flow To Equity Per Share--1.9970.280+614%0.261+666%0.604+231%0.637+214%
Usd Market Cap2773095356.160+19%2251156660.4402330678283.510-3%3730940130.240-40%3366902820.558-33%3206574114.817-30%
Usd Price Per Share33.960+20%27.22028.455-4%45.690-40%41.215-34%39.252-31%
Usd Profit--142797000.000-30024500.000+121%-62904000.000+144%-50756800.000+136%-49539523.810+135%
Usd Revenue--316192000.00094427250.000+235%15230000.000+1976%24525750.000+1189%23357857.143+1254%
Usd Total Gains Per Share--2.3270.721+223%-0.286+112%0.520+348%0.573+306%
 EOD+4 -4MRQTTM+27 -7YOY+27 -75Y+27 -910Y+27 -9

4.2. Fundamental Score

Let's check the fundamental score of Beam Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154.917
Price to Book Ratio (EOD)Between0-12.862
Net Profit Margin (MRQ)Greater than00.452
Operating Margin (MRQ)Greater than00.420
Quick Ratio (MRQ)Greater than19.456
Current Ratio (MRQ)Greater than15.891
Debt to Asset Ratio (MRQ)Less than10.328
Debt to Equity Ratio (MRQ)Less than10.487
Return on Equity (MRQ)Greater than0.150.146
Return on Assets (MRQ)Greater than0.050.098
Total8/10 (80.0%)

4.3. Technical Score

Let's check the technical score of Beam Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.906
Ma 20Greater thanMa 5036.092
Ma 50Greater thanMa 10032.049
Ma 100Greater thanMa 20029.543
OpenGreater thanClose33.560
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -2,4301,665-765-1,250-2,015-9-2,0242,628604
Income before Tax  -37,349-59,111-96,46013,684-82,776-13,312-96,088240,251144,163
Net Income  -38,349-45,682-84,0311,255-82,776-13,312-96,088238,885142,797
EBIT  -88,985-9,943-98,928-15,455-114,3831,448-112,935245,793132,858
EBITDA  -133,01041,575-91,435-18,132-109,5671,819-107,748245,968138,220
Operating Income  -88,985-9,943-98,928-3,220-102,148-6,119-108,267241,125132,858
Net Income from Continuing Operations  -38,349-58,111-96,46013,684-82,776-13,312-96,088238,885142,797



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,459,714
Total Liabilities478,385
Total Stockholder Equity981,329
 As reported
Total Liabilities 478,385
Total Stockholder Equity+ 981,329
Total Assets = 1,459,714

Assets

Total Assets1,459,714
Total Current Assets1,211,043
Long-term Assets248,671
Total Current Assets
Cash And Cash Equivalents 435,895
Short-term Investments 753,981
Other Current Assets 21,167
Total Current Assets  (as reported)1,211,043
Total Current Assets  (calculated)1,211,043
+/-0
Long-term Assets
Property Plant Equipment 237,806
Long-term Assets Other 2,146
Long-term Assets  (as reported)248,671
Long-term Assets  (calculated)239,952
+/- 8,719

Liabilities & Shareholders' Equity

Total Current Liabilities205,565
Long-term Liabilities272,820
Total Stockholder Equity981,329
Total Current Liabilities
Short-term Debt 13,262
Accounts payable 1,617
Other Current Liabilities 121,980
Total Current Liabilities  (as reported)205,565
Total Current Liabilities  (calculated)136,859
+/- 68,706
Long-term Liabilities
Capital Lease Obligations 172,689
Long-term Liabilities Other 3,021
Long-term Liabilities  (as reported)272,820
Long-term Liabilities  (calculated)175,710
+/- 97,110
Total Stockholder Equity
Common Stock816
Retained Earnings -1,189,889
Accumulated Other Comprehensive Income 604
Other Stockholders Equity 2,169,798
Total Stockholder Equity (as reported)981,329
Total Stockholder Equity (calculated)981,329
+/-0
Other
Capital Stock816
Cash and Short Term Investments 1,189,876
Common Stock Shares Outstanding 82,702
Current Deferred Revenue68,706
Liabilities and Stockholders Equity 1,459,714
Net Debt -262,722
Net Invested Capital 981,329
Net Working Capital 1,005,478
Property Plant and Equipment Gross 287,988
Short Long Term Debt Total 173,173



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
> Total Assets 
0
167,012
0
180,547
170,553
156,099
322,638
299,975
278,273
451,677
693,241
893,078
1,156,555
1,474,453
1,453,402
1,418,375
1,350,250
1,341,714
1,332,352
1,353,887
1,290,534
1,459,714
1,459,7141,290,5341,353,8871,332,3521,341,7141,350,2501,418,3751,453,4021,474,4531,156,555893,078693,241451,677278,273299,975322,638156,099170,553180,5470167,0120
   > Total Current Assets 
0
148,275
0
129,389
114,779
94,544
259,634
234,829
208,707
308,321
514,580
677,993
941,424
965,647
1,239,484
1,166,115
1,108,912
1,092,896
1,083,031
1,094,805
1,039,541
1,211,043
1,211,0431,039,5411,094,8051,083,0311,092,8961,108,9121,166,1151,239,484965,647941,424677,993514,580308,321208,707234,829259,63494,544114,779129,3890148,2750
       Cash And Cash Equivalents 
0
146,443
0
37,852
37,764
37,221
126,050
125,301
202,220
162,171
97,241
212,015
612,023
965,647
296,821
1,166,115
1,094,554
232,767
249,771
225,544
169,049
435,895
435,895169,049225,544249,771232,7671,094,5541,166,115296,821965,647612,023212,01597,241162,171202,220125,301126,05037,22137,76437,8520146,4430
       Short-term Investments 
0
0
0
88,908
73,128
54,627
127,392
102,649
64,317
137,500
406,238
403,264
321,382
405,653
925,779
900,492
938,043
845,367
809,700
847,472
846,408
753,981
753,981846,408847,472809,700845,367938,043900,492925,779405,653321,382403,264406,238137,50064,317102,649127,39254,62773,12888,908000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
50,000
0
300,000
0
0
0
0
0
0
0
0
00000000300,000050,00000000000000
       Other Current Assets 
0
1,832
0
2,629
3,887
2,696
6,192
6,879
6,487
8,650
11,101
12,714
8,019
7,360
16,884
13,775
14,358
14,762
23,560
21,789
24,084
21,167
21,16724,08421,78923,56014,76214,35813,77516,8847,3608,01912,71411,1018,6506,4876,8796,1922,6963,8872,62901,8320
   > Long-term Assets 
0
18,737
0
51,158
55,774
61,555
63,004
65,146
69,566
143,356
178,661
215,085
215,131
508,806
213,918
252,260
241,338
248,818
249,321
259,082
250,993
248,671
248,671250,993259,082249,321248,818241,338252,260213,918508,806215,131215,085178,661143,35669,56665,14663,00461,55555,77451,158018,7370
       Property Plant Equipment 
0
16,944
0
36,771
37,957
43,247
46,928
48,595
51,180
125,372
158,788
169,658
174,702
186,976
199,831
223,516
226,714
234,133
237,981
242,278
239,661
237,806
237,806239,661242,278237,981234,133226,714223,516199,831186,976174,702169,658158,788125,37251,18048,59546,92843,24737,95736,771016,9440
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
29,430
24,538
0
0
0
0
0
0
0
0
0
00000000024,53829,43000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
19,873
15,997
15,891
14,470
14,087
14,969
14,624
14,685
0
16,804
0
0
0016,804014,68514,62414,96914,08714,47015,89115,99719,8730000000000
> Total Liabilities 
0
32,984
0
36,896
43,832
55,154
61,244
69,153
78,202
206,116
270,812
344,527
302,741
647,715
624,334
618,214
635,773
608,240
570,846
542,244
511,593
478,385
478,385511,593542,244570,846608,240635,773618,214624,334647,715302,741344,527270,812206,11678,20269,15361,24455,15443,83236,896032,9840
   > Total Current Liabilities 
0
25,587
0
15,310
19,909
29,138
31,440
38,950
47,451
102,337
102,086
128,715
101,391
213,435
218,798
212,278
238,859
223,595
219,925
209,536
220,365
205,565
205,565220,365209,536219,925223,595238,859212,278218,798213,435101,391128,715102,086102,33747,45138,95031,44029,13819,90915,310025,5870
       Short-term Debt 
0
0
0
1,962
2,752
4,337
4,699
4,698
4,340
4,218
3,885
3,491
6,484
7,540
9,359
9,512
9,823
10,380
11,157
11,492
11,951
13,262
13,26211,95111,49211,15710,3809,8239,5129,3597,5406,4843,4913,8854,2184,3404,6984,6994,3372,7521,962000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
2,142
2,189
2,238
2,287
2,337
2,389
0
0
0
0
0
0
0000002,3892,3372,2872,2382,1892,1420000000000
       Accounts payable 
0
7,351
0
3,587
3,857
7,846
6,101
6,154
6,569
6,314
7,983
8,030
7,282
7,474
6,266
7,095
7,024
9,029
14,063
6,886
3,177
1,617
1,6173,1776,88614,0639,0297,0247,0956,2667,4747,2828,0307,9836,3146,5696,1546,1017,8463,8573,58707,3510
       Other Current Liabilities 
0
18,236
0
4,596
7,204
10,335
13,342
21,139
19,507
77,571
80,050
107,170
74,803
112,151
88,124
56,005
62,110
68,212
51,968
52,031
51,753
121,980
121,98051,75352,03151,96868,21262,11056,00588,124112,15174,803107,17080,05077,57119,50721,13913,34210,3357,2044,596018,2360
   > Long-term Liabilities 
0
7,397
0
21,586
23,923
26,016
29,804
30,203
30,751
103,779
168,726
215,812
201,350
434,280
405,536
405,936
396,914
384,645
350,921
332,708
291,228
272,820
272,820291,228332,708350,921384,645396,914405,936405,536434,280201,350215,812168,726103,77930,75130,20329,80426,01623,92321,58607,3970
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
38,160
78,843
64,632
296,463
267,098
240,164
230,451
214,866
0
167,982
0
0
00167,9820214,866230,451240,164267,098296,46364,63278,84338,1600000000000
> Total Stockholder Equity
0
134,028
0
143,651
126,721
100,945
261,394
230,822
200,071
245,561
422,429
548,551
853,814
826,738
829,068
800,161
714,477
733,474
761,506
811,643
778,941
981,329
981,329778,941811,643761,506733,474714,477800,161829,068826,738853,814548,551422,429245,561200,071230,822261,394100,945126,721143,6510134,0280
   Common Stock
0
56
0
289
360
73
491
496
504
573
617
645
677
684
698
703
705
712
744
780
794
816
816794780744712705703698684677645617573504496491733602890560
   Retained Earnings Total Equity00-1,236,598-1,153,8220-1,019,013-909,438-837,488-768,2740000000000000
   Accumulated Other Comprehensive Income 
0
-661
0
83
48
16
-344
173
41
-9
-24
31
19
-50
-2,709
-4,190
-4,674
-2,430
-765
-2,015
-2,024
604
604-2,024-2,015-765-2,430-4,674-4,190-2,709-501931-24-941173-3441648830-6610
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,594,378
1,668,567
1,713,086
1,737,459
0
1,915,349
2,049,476
0
0
002,049,4761,915,34901,737,4591,713,0861,668,5671,594,3780000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
7,917
0
3,944
301,507
1,851
172,111
197,898
223,425
642,633
327,791
1,223,324
1,556,685
1,594,378
1,668,567
1,713,086
1,737,459
1,792,554
1,915,349
2,049,476
2,112,857
2,169,798
2,169,7982,112,8572,049,4761,915,3491,792,5541,737,4591,713,0861,668,5671,594,3781,556,6851,223,324327,791642,633223,425197,898172,1111,851301,5073,94407,9170



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue377,709
Cost of Revenue-20,012
Gross Profit357,697357,697
 
Operating Income (+$)
Gross Profit357,697
Operating Expense-534,182
Operating Income-176,485-176,485
 
Operating Expense (+$)
Research Development437,381
Selling General Administrative116,813
Selling And Marketing Expenses20,012
Operating Expense534,182574,206
 
Net Interest Income (+$)
Interest Income0
Interest Expense-46,676
Other Finance Cost-88,899
Net Interest Income42,223
 
Pretax Income (+$)
Operating Income-176,485
Net Interest Income42,223
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-131,161-221,809
EBIT - interestExpense = -223,161
-131,161
-85,851
Interest Expense46,676
Earnings Before Interest and Taxes (EBIT)-176,485-84,485
Earnings Before Interest and Taxes (EBITDA)-156,473
 
After tax Income (+$)
Income Before Tax-131,161
Tax Provision-1,000
Net Income From Continuing Ops-313,673-132,161
Net Income-132,527
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses554,194
Total Other Income/Expenses Net45,324-42,223
 

Technical Analysis of Beam Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Beam Therapeutics Inc. The general trend of Beam Therapeutics Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Beam Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Beam Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 49.50 < 50.74 < 51.60.

The bearish price targets are: 31.09 > 30.62 > 30.29.

Tweet this
Beam Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Beam Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Beam Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Beam Therapeutics Inc. The current macd is 0.05779083.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Beam Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Beam Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Beam Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Beam Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartBeam Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Beam Therapeutics Inc. The current adx is 26.78.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Beam Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Beam Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Beam Therapeutics Inc. The current sar is 35.49.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Beam Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Beam Therapeutics Inc. The current rsi is 47.91. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Beam Therapeutics Inc Daily Relative Strength Index (RSI) ChartBeam Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Beam Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Beam Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Beam Therapeutics Inc Daily Stochastic Oscillator ChartBeam Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Beam Therapeutics Inc. The current cci is -93.70138528.

Beam Therapeutics Inc Daily Commodity Channel Index (CCI) ChartBeam Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Beam Therapeutics Inc. The current cmo is -12.1574284.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Beam Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartBeam Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Beam Therapeutics Inc. The current willr is -81.26009693.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Beam Therapeutics Inc Daily Williams %R ChartBeam Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Beam Therapeutics Inc.

Beam Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Beam Therapeutics Inc. The current atr is 2.21365316.

Beam Therapeutics Inc Daily Average True Range (ATR) ChartBeam Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Beam Therapeutics Inc. The current obv is 28,408,875.

Beam Therapeutics Inc Daily On-Balance Volume (OBV) ChartBeam Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Beam Therapeutics Inc. The current mfi is 25.35.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Beam Therapeutics Inc Daily Money Flow Index (MFI) ChartBeam Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Beam Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Beam Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Beam Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.906
Ma 20Greater thanMa 5036.092
Ma 50Greater thanMa 10032.049
Ma 100Greater thanMa 20029.543
OpenGreater thanClose33.560
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Beam Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Beam Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Beam Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Beam Therapeutics Inc

I send you an email if I find something interesting about Beam Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Beam Therapeutics Inc.

Receive notifications about Beam Therapeutics Inc in your mailbox!